Private Company Edition: Bain will invest across private and public drug, device, diagnostic and tool companies. Also, Candid debuted with $370m in initial funding, Superluminal closed a $120m series A round, PanTera raised €93m ($102.4m) in series A cash and F2G brought in $100m.

With only one inflammatory bowel disease product, Lilly is betting big on Morphic and its Phase II oral integrin MORF-057, which would directly compete with Takeda blockbuster Entyvio.

Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.

A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.